论文部分内容阅读
目的观察痰热清注射液治疗小儿肺炎支原体肺炎的临床疗效。方法选取2014年2月—2016年2月无锡市儿童医院收治的肺炎支原体肺炎患儿143例,随机分为对照组71例和观察组72例。对照组患儿入院后给予常规治疗,观察组患儿在对照组治疗基础上加用痰热清注射液;两组患儿均连续治疗7 d。比较两组患儿治疗前后莱塞斯特咳嗽生命质量问卷(LCQ)评分、炎性因子〔白介素6(IL-6)、白介素10(IL-10)、C反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)〕水平,临床症状和体征改善时间及临床疗效。结果治疗前两组患儿LCQ评分比较,差异无统计学意义(P>0.05);治疗后观察组患儿LCQ评分高于对照组(P<0.05);治疗后两组患儿LCQ评分均高于治疗前(P<0.05)。治疗前两组患儿IL-6、IL-10、CRP、TNF-α水平比较,差异无统计学意义(P>0.05);治疗后观察组患儿IL-6、IL-10、CRP、TNF-α水平低于对照组(P<0.05);治疗后两组患儿IL-6、IL-10、CRP、TNF-α水平均低于治疗前(P<0.05)。观察组患儿发热、咳嗽、啰音及胸部X线检查结果好转时间均短于对照组(P<0.05)。观察组患儿临床疗效优于对照组(P<0.05)。结论在常规治疗基础上加用痰热清注射液治疗小儿肺炎支原体肺炎的临床疗效确切,可有效降低患儿炎性因子水平、缓解患儿临床症状和体征。
Objective To observe the clinical efficacy of Tanreqing Injection in the treatment of children with Mycoplasma pneumoniae pneumonia. Methods 143 children with Mycoplasma pneumoniae pneumonia admitted from Wuxi Children’s Hospital from February 2014 to February 2016 were randomly divided into control group (n = 71) and observation group (n = 72). Children in the control group were given routine treatment after admission. The children in the observation group were given Tanreqing Injection on the basis of the control group. The children in both groups were treated for 7 consecutive days. The quality of life (QOL) of the patients in the two groups was compared before and after treatment with the Cesarean section. The scores of inflammatory cytokines (interleukin 6, interleukin 10, CRP, tumor necrosis factor alpha (TNF-α)〕 levels, clinical symptoms and signs of improvement and clinical efficacy. Results There was no significant difference in LCQ score between the two groups before treatment (P> 0.05). After treatment, the LCQ score of the observation group was higher than that of the control group (P <0.05). After treatment, the LCQ scores of both groups were high Before treatment (P <0.05). The levels of IL-6, IL-10, CRP and TNF-α in the two groups before treatment were not significantly different (P> 0.05). After treatment, the levels of IL-6, IL- (P <0.05). The levels of IL-6, IL-10, CRP and TNF-α in the two groups after treatment were lower than those before treatment (P <0.05). The fever, cough, rales and chest X-ray findings in the observation group were all shorter than those in the control group (P <0.05). The clinical efficacy of the observation group was better than that of the control group (P <0.05). Conclusion The addition of Tanreqing Injection on the basis of routine treatment is effective in treating children with Mycoplasma pneumoniae pneumonia, which can effectively reduce the level of inflammatory cytokines in children and relieve the clinical symptoms and signs of children.